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Ten-year survival of second kidney transplants: Impact of im-
munologic factors and renal function at 12 months.
Background. The aim of the present study was to assess long-
term survival of cadaveric second kidney allografts performed
in our center and to determine risk factors predictive of long-
term graft outcome.
Methods. Of 1704 kidney transplantations performed be-
tween January 1985 and March 1998, 233 were second grafts.
The majority of the recipients were sensitized. All patients were
treated with the same quadruple immunosuppressive regimen.
Results. Kaplan-Meier analysis documented graft survival
of 89% at 1 year, 76% at 5 years, and 53% at 10 years. Graft
survival was similar for second and primary kidney transplants
performed during the same period of time. When long-term
second graft survival was examined, only two risk factors were
found to be significant: (1) the degree of human leukocyte
antigen (HLA) DR mismatch (MM) and (2) the number of
acute rejection episodes. Multivariate analysis of several pre-
and posttransplant variables also confirmed the importance of
HLA MM (DR BA), but also, identified serum creatinine
at 12 months as the most significant predictor of graft survival.
In addition, the Cox proportional hazards model revealed that
only the year of transplantation had an independent significant
effect on acute rejection occurrence (RR 0.591, 95%CI 0.437
to 0.801, P  0.0007). Indeed, the incidence of acute rejection
was found to decrease over time (44% of patients experienced
at least one episode of acute rejection before 1990 vs. 17%
after 1990).
Conclusion. Finally, second graft long-term outcome shows
an improved evolution according to the time period resulting
from a strong decrease in acute rejection incidence and the
impact of creatinine at 12 months.
Despite the significant improvements that have oc-
curred since the introduction of cyclosporine (CsA), long-
term renal allograft survival continues to be an area of
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concern [1]. After CsA was introduced in 1985, the short-
term renal allograft survival rate improved by 10% to
20%, but the rate of chronic graft loss still remains high.
Between 5% and 24% of all kidney transplants are lost
because of chronic rejection during the first 5 years after
transplantation, and 50% to 80% of patients undergoing
transplantation who return for dialysis treatment do so
because of this [2]. Therefore, renal allograft failure has
become one of the most common causes of end-stage
renal disease (ESRD), accounting for 25% to 30% of
patients awaiting renal transplantation [3].
Repeat transplantation confers a robust survival advan-
tage to patients over dialysis. Indeed, it has been shown
that the survival benefits of primary kidney transplanta-
tion can also be extrapolated to repeat transplantation [4].
Retransplanted patients are an immunologically unique
group since they have already experienced graft loss and
have been exposed to alloantigens. Consequently, these
patients are often sensitized. Retransplanted patients ac-
cumulate several risk factors, which have been initially
associated with poor outcome, including high levels of
panel reactive antibody (PRA), and previous graft short
survival (3 to 6 months) [5–7]. Regraft survival rates for
cadaveric donor renal allografts have historically been
lower than those of primary allograft recipients [5, 8, 9].
However, the success rates for renal retransplantation
have significantly improved in recent years as a result
of improved pretransplant screening and posttransplant
management, including sensitive cross matching, better
human leukoctye antigen (HLA) matching, and more
potent immunosuppressive regimens [10]. It is now re-
ported that 1-year graft survival rates for second kidney
transplants approach those of primary transplantations
[11–14]. Risk factors for early graft failure of renal re-
transplantation have been well studied. Nevertheless, in
the CsA era, long-term survival of second kidney trans-
plantation remains not well defined.
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Among the 25,659 kidney transplantations performed
in France between 1989 and 1999, 13.3% were retrans-
plantations, reflecting the annual rate of second kidney
transplantations performed in our center (National Report
from the “Etablissement Franc¸ais des Greffes” [EFG],
2000). The expanding list of second kidney graft candi-
dates reached 42% of the total population awaiting a
transplant in September 1998. The main reasons for this
disproportionate allocation of kidney transplants to re-
transplantation candidates are multiple and mainly in-
clude high anti-HLA sensitization level and the incidence
of positive cross matches. As a consequence, waiting
time for retransplantation is significantly correlated to
the immunization degree. Therefore, analysis of second
graft long-term survival, as well as a better understanding
of patient specificity and management, are required for
the optimal treatment of chronic renal failure.
In this study, we report our experience with 233 second
consecutive cadaver kidney transplantations performed
between January 1985 and March 1998 in adult recipients
having received the same quadruple immunosuppressive
regimen. Most of the recipients (69%) were sensitized
(anti-T or anti-B PRA 25%), including 50% of highly
sensitized patients (anti-T or anti-B PRA80%), which
corresponded to 34.3% of the total population. Our pur-
pose was to assess the 10-year survival of second kidney
transplants and to determine, using univariate and multi-
variate analyses, the risk factors associated with regraft
outcome.
METHODS
Patients
Among 1704 cadaver kidney transplantations per-
formed in adults at our institution between January 1985
and March 1998, 233 were second grafts and 1174 were
primary grafts. Combined kidney-pancreas transplanta-
tions were excluded from the study. No type II diabetics
were present in our cohort. The minimum follow-up
period was 12 months after transplantation.
Patients were carefully monitored while on the waiting
list. Sera were harvested and tested for the presence of
anti-HLA antibodies systematically every 3 months, as
well as at 2 and 3 weeks after every blood transfusion
or first transplant nephrectomy. Anti-HLA antibodies
were detected by complement-dependent cytotoxicity
assay performed on B and T cells separately from on a
panel of 36 representative HLA-typed donors.
Patients were selected for transplantation according
to ABO compatibility. Matching policy required, if possi-
ble, a minimum of four HLA compatibilities, with prior-
ity given to the patients with high levels of PRA. HLA
repeated mismatches (MM) were allowed only when the
recipient had not developed anti-HLA class I or anti-
HLA class II antibodies also specific for the second donor.
The pretransplant cross match was performed by com-
plement-dependent cytotoxicity according to the National
Institutes of Health (NIH) guidelines. T-cell cross match
on historic as well as current sera had to be negative.
However, a positive lymphocytotoxic B-cell cross match,
without anti-donor T reactivity, was not considered as a
contraindication to transplantation [15]. As autoantibod-
ies are generally of the immunoglobulin M (IgM) isotype,
the cross match was also carried out in the presence
of dithiothreitol to discriminate between IgM and IgG
antibodies.
The data were extracted, computerized, and validated
from a standardized database “DIVAT network” (Don-
ne´es Informatise´es et VAlide´es en Transplantation) [16, 17].
In this procedure, a specialized clinical research assistant,
independent of the medical team, prospectively collected
the pre- and postgraft data of all patients transplanted
at our institution. An annual medical audit attested the
database validity, with the level of error below 1%.
The database included donor characteristics (age, gen-
der, serum creatinine), recipient variables (age at trans-
plant, gender, anti-T and anti-B peak PRA level, cause of
patient death), transplant variables [cold ischemia time,
HLA-A, HLA-B, HLA-DR MM, repeat MM HLA anti-
gens, result of the T- and B-cell cross matches, delayed
graft function (DGF), acute rejection episodes, serum cre-
atinine and daily proteinuria at 3 and 12 months, cause
of renal failure], and first graft characteristics (duration
of previous allograft function, interval between the two
transplants, cause of initial graft loss, and information
on immunosuppressive treatment).
Return to chronic dialysis program or death with a
functioning graft was considered as a graft loss. Acute
rejection was identified by standard clinical criteria in
conjunction with renal biopsy (excepted if contraindica-
tion) analyzed according to the Banff classification. DGF
was defined as the need for at least one dialysis session
during the first 7 days after transplant, and also, as the
number of days required to reach a Cockcroft-calculated
creatinine clearance of at least 10 mL/min.
Immunosuppression protocol
Although the immunosuppressive drugs diversified over
the study period, all patients were treated according to the
same quadruple sequential immunosuppressive protocol,
consisting of an induction therapy by anti-lymphocyte
polyclonal or monoclonal antibody, delayed introduction
of calcineurin inhibitor, and a “standard” maintenance
therapy, as described below.
Induction therapy consisted of polyclonal anti-lym-
phocyte preparations for the majority (N  202) [rabbit
antithymoglobuline (ATG) at a dose of 1 mg/kg/day for
146 recipients, or, horse anti-lymphocyte globulin (ALG)
for 56 patients] (IMTIX-SangStat, Lyon, France). In a
few cases (N 31), an anti-interleukin-2 receptor mono-
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clonal antibody (33B3.1) (N  28) or monoclonal anti-
body OKT3 (N 3) was used for the induction protocol.
In all cases for the induction protocol, the bioreagent
was administered in the immediate posttransplant period
for 10 to 14 days, associated with azathioprine (2 mg/kg/
day) and corticosteroid (prednisone) at a dose of 1 mg/
kg/day. Since June 1996, mycophenolate mofetil (MMF)
(2 g/day) was introduced instead of azathioprine (N 27
patients). Azathioprine and MMF doses were adjusted
according to the white blood cell count.
CsA (Sandimmun, Novartis Pharma SA, Rueil-Mal-
maison, France) was begun 1 day before the end of
induction therapy, or, in case of DGF, when the serum
creatinine reached a level below 300 mol/l, at a dose of
8 mg/kg/day. The CsA dosage was adjusted to maintain a
trough level of 150 to 250 ng/mL, as measured by whole-
blood radioimmunoassay. The microemulsion formula-
tion of CsA (Ne´oral, Novartis Pharma SA, Rueil-Mal-
maison, France) (N 21) was introduced concomitantly
with MMF.
The prednisone dose was decreased 10 mg every 5
days to a maintenance dose of 10 mg/day, and slowly
tapered after 3 months if no acute rejection had occurred,
if serum creatinine level was less than 200 mol/l, and
if azathioprine or MMF were tolerated. Ultimately, 47%
were under corticosteroid-free therapy at 1 year. There-
fore, the “standard” maintenance therapy was CsA and
azathioprine or MMF.
Acute rejection episodes were treated with intrave-
nous boluses of methylprednisolone for 5 consecutive
days (5 mg/kg/day for 2 days, tapered by 1 mg/kg/day
every day), followed by decreasing doses of oral predni-
sone. ATG or OKT3 were used in the case of unrespon-
siveness to corticosteroid or severe rejections (Banff
grade II or III).
Statistical analysis
Graft and patient survival analysis was performed us-
ing the Kaplan-Meier method, and statistical differences
between curves were assessed using the log-rank test. To
determine the risk factors of graft failure, the Cox propor-
tional hazards model was applied. The follow-up dura-
tion and the year of transplantation were included in
this model. The recipients (N  7) with a nonfunctional
graft or with early graft failure (3 weeks posttrans-
plantation) were not used in the multivariate analysis.
A Cox proportional hazards model was also created in
order to study the predictive factors of one acute rejection
episode. The acute rejection was analyzed as a time-
dependent variable with the date of first rejection inci-
dence considered for each patient. Baseline characteris-
tics among groups were compared using chi-square test
and analysis of variance (ANOVA) for categoric and
continuous variables. A P value 0.05 was considered
significant.
Table 1. Demographic and baseline characteristics of study’s
patients (N  233) and control group
(primary transplants, N  1174)
Characteristic Second grafts Primary grafts
Recipient age years
MeanSD 40.512 44.814
Range 16–73 15–73
Recipient gender number (%)
Male 147 (63%) 741 (63%)
Donor age years
MeanSD 3414 3515
Range 8–65 1–69
Donor gender number (%)
Male 168 (72%) 848 (72%)
Peak PRA (%SD)
anti-T 41.636 11%24
anti-B 42%31 12%22
PRA number (%)
anti-T and anti-B 25% 72 (31%) 980 (83.5%)
anti-T or anti-B 25% et 80% 81 (34.7%) 124 (10.5%)
anti-T or anti-B 80% 80 (34.3%) 70 (6%)
No. of total HLA MM %
2 150 (64.4%) 282 (24%)
2 83 (35.6%) 892 (76%)
No. of HLA-A MM %
0 92 (39.5%)
1 117 (50.2%)
2 24 (10.3%)
No. of HLA-B MM %
0 59 (25.3%)
1 130 (55.8%)
2 44 (18.9%)
No. of HLA-DR MM %
0 112 (48.1%)
1 104 (44.6%)
2 17 (7.3%)
Cold ischemia time hours
MeanSD 32.49.6 32.610.2
Range 9.5–51 2.5–60
DGF
No. of days (creatinine
10 mL/mn)a (meanSD) 8.26.7 8.37.7
Dialysis sessiona  0 number (%) 116 (53.4%) 606 (51.6%)
Survival time of first transplant years 3.43.8
Abbreviations are: PRA, panel reactive antibody; HLA, human leukocyte
antigen; MM, mismatch; DGF, delayed graft function.
a Described in Methods section
RESULTS
Population characteristics
Between January 1985 and March 1998, 233 second
grafts were performed at our institution, corresponding
to 13.7% of 1704 kidney transplants. On average, 19 sec-
ond transplants were performed annually. The character-
istics of the recipients, donors, and grafts (second and
primary) are reported in Table 1.
Most of the recipients were sensitized: 69% had a PRA
(anti-T or anti-B) greater than 25%, including 50% of
hyperimmunized patients (anti-T or anti-B PRA80%),
which corresponded to 34.3% of the total population.
The number of HLA-A, HLA-B, or HLA-DR MM was
two or less for 64.4% of patients. Moreover, it was sig-
nificantly correlated to the level of anti-T or anti-B allo-
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Fig. 1. Long-term graft survival for second and primary transplants
performed in our center between 1985 and 1998.
immunization (peak anti-T PRA  49% for 2 MM,
and 28.5% for 2 MM, P  0.00001).
In our cohort, the interval between primary and sec-
ond transplants was less than 1 year for 23% of patients
and more than 6 years for 21.5% of patients. First grafts
survived for less than 1 year in 43.3% of patients. The
cause of first graft failure was acute rejection for 5% of
patients or chronic rejection for 72% of patients. Only
42.5% of patients had received CsA during first trans-
plant, associated to ATG for 32.6%.
Patient and graft survival
Patient survival rates analyzed by Kaplan-Meier were
97%, 92%, and 87%, at 1, 5, and 10 years, respectively.
Patient survival was not statistically dissimilar for the
recipients of second and primary kidney transplants in
our center (data not shown). Among the 233 second
graft recipients, 16 patients died with a functional trans-
plant and two died within the 3 months following their
return to chronic dialysis. Cardiovascular diseases repre-
sented the main cause of death, and malignancy was the
cause of death for two patients.
Kaplan-Meier analysis documented graft survival of
89% at 1 year, 76% at 5 years, and 53% at 10 years.
Among causes of retransplant loss, death with function-
ing graft accounted for 19%, acute rejection for 14.3%,
and chronic rejection for 46.5%.
Therefore, despite the fact that the immunologic char-
acteristics were very different, recipients of second trans-
plants had an overall graft survival rate similar to that
of the 1174 primary kidney cadaveric transplants per-
formed during the studied period (Fig. 1). Furthermore,
comparison of survival of second kidney with the group
of 172 first transplants performed with a similar number
of total HLA MM (2) and immunosuppression (ATG
and CsA) demonstrated identical graft survival curves
(Fig. 2). This indicates that the good survival time ob-
served in these patients was not directly due to a better
matching policy and treatment.
Fig. 2. Comparison of second kidney graft survival with the group of
first transplants performed with human leukocyte antigen (HLA)-A,
HLA-B, HLA-DR mismatches (MM)  2 and treated with antithymo-
globuline (ATG) and cyclosporine A (CsA).
Fig. 3. Effect of DR matching on second graft survival.
Risk factors of second graft loss
When long-term survival of second graft was examined
on the basis of Kaplan-Meier estimates, only two factors
were found to be significant: (1) the degree of HLA-DR
MM and (2) the number of acute rejection episodes. No
significant impact on graft outcome was found for the
following parameters: donor/recipient age and gender,
anti-HLA immunization, positive B-cell cross match,
DGF, and first transplant parameters.
Graft survival rates at 5 and 10 years were 82% and
69% in the absence of DR MM versus 73% and 54%
for at least one DR MM (1) (P  0.02) (Fig. 3). Acute
rejection was the second significant factor associated with
long-term graft survival (Fig. 4). Recipients with no re-
jection episodes had significantly better long-term graft
survival than recipients with rejection (P  0.001). Fur-
thermore, the impact of acute rejection increased with
the number of acute rejection episodes. This effect was
still significant beyond the first year of transplantation.
In order to determine other independent risk factors
associated with poor long-term outcome, a multivariate
analysis of graft survival was then performed (Table 2).
Coupel et al: Long-term survival of second kidney transplants678
Fig. 4. Effect of acute rejection (AR) on second graft survival.
This analysis further demonstrated the dominant effect
of DR MM, which was the major predictor of second
graft loss (RR  2.8). Associated HLA-B MM further
significantly increased the risk of graft failure. Conse-
quently, the increasing degree of HLA-A MM was corre-
lated to a lower hazard, since it strongly reflected the
respective matching for HLA-B and HLA-DR.
One-year serum creatinine is the more significant post-
transplant variable predicting graft loss in the multivari-
ate analysis (P  0.0002). A difference of 30 mol/L
between serum creatinine levels at 1 year increased the
risk of graft loss by 15%. Mean of serum creatinine at
12 months was 217 mol/L for graft transplants lost in
the long-term follow-up, and 144 mol/L for functioning
transplants. In addition, transplant function was strongly
correlated with the occurrence of at least one acute rejec-
tion episode (mean serum creatinine at 12 months, 218
mol/L versus 140 mol/L, P  0.0001).
Predictive factors for acute rejection
The Cox proportional hazard model revealed that only
the period in time at which the transplantation was per-
formed had an independent significant effect on acute
rejection occurrence (RR 0.591, 95% CI 0.437 to 0.801,
P  0.0007). Indeed, the incidence of acute rejection
was found to decrease over time. Before January 1990,
44% of patients experienced at least one episode of acute
rejection. This decreased to 17% after 1990 (2  19.78,
P  0.001). In addition, the rate of acute rejection was
only 7.5% for the last 3 years. This decreasing incidence
of acute rejection is strongly correlated with the improve-
ment of graft survival over time: the risk of graft loss
decreased by 36.6% from 1985 to 1998. These results
were even confirmed when outcome of regraft was ana-
lyzed over the first year of transplantation. Finally, the
time-related effect was still significant for patients who
received one well-matched kidney (total HLA MM2).
Interestingly, we also observed that two others vari-
ables, including donor age (50 years versus 50 years,
P  0.0523) and cold ischemia period (24 hours versus
24 hours, P  0.0552) approached significance in pre-
dicting occurrence of acute rejection.
Table 2. Multivariate analysis of risk factors of long-term
graft survivala
Relative 95% Confidence
Variable risk (RR) interval (95% CI) P value
HLA-DR MM 2.803 1.398–5.618 0.0037
HLA-B MM 1.889 1.066–3.338 0.0292
HLA-A MM 0.469 0.248–0.884 0.0192
Serum creatinine
at 12 months 1.238 1.106–1.386 0.0002
a Variables included in the Cox model were donor age and gender, donor
serum creatinine, recipient age and gender, anti-T and anti-B peak panel reactive
antibody (PRA) level, cause of patient death, cold ischemia time, human leuko-
cyte antigen (HLA)-A, HLA-B, HLA-DR mismatch (MM), repeat MM HLA
antigens, result of the T-cell and B-cell cross matches, delayed graft failure
(DGF), acute rejection episodes, serum creatinine and daily proteinuria at 3 and
12 months, cause of renal failure, and first graft characteristics (duration of previous
allograft function, interval between the two transplants, cause of initial graft loss,
and information on immunosuppressive treatment).
DISCUSSION
In this paper, we report on a single-center analysis
of 233 retransplant recipients who received a cadaveric
kidney between 1985 and 1998. The great advantage
of such a single-center study is better homogeneity of
transplant recipients with respect to medical manage-
ment and the ability to collect detailed data on all recipi-
ents [18]. The limitation of a single-center study is the
cohort size. Most previously published data included less
than 100 patients, with low statistical power for some
parameters [12, 19–21]. Most of the studies including a
larger cohort of second kidney recipients were multicen-
tric [22, 23] but rarely monocentric [5, 6]. Furthermore,
unicentric study allows analysis of both nonimmunologic
and immunologic factors, which are usually lacking in
multicentric studies.
The predominant characteristics of our population
were the high level of sensitized recipients (69% with
PRA 25%), the high level of HLA matching (2 MM
for 64% of recipients) and long cold ischemia time (over
36 hours for 41% of recipients) resulting from organ
shipping to fit with the HLA matching requirement for
sensitized patients and to cross match tests.
One important point in our study is that both short-
term and long-term graft survival for retransplantations
were good and not significantly different from primary
transplants at our center. Based on analyses of kidney
transplants reported to the UNOS Scientific Renal
Transplant Registry from 1991 to 1997, the data of Cecka
[23] showed that the 5-year patient and graft survival
rates were 82% and 63%, respectively, for 50,291 recipi-
ents of cadaver donor kidneys. In this study, the survival
rates of second transplants were only 2% less than for
first transplants, whether the kidney was from a living
or a cadaver donor [23]. In contrast, Moss et al [24]
showed in a single-center study that short-term outcome
for primary and retransplant recipients has been similar;
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however, long-term outcome seems worse for retrans-
plant recipients.
It should also be emphasized that, despite repeated
immunosuppression, recipient survival was as good for
second as for primary grafts, and the incidence of cancer,
and most particularly lymphoma, was not increased
(3.4% versus 2.8% for second and primary grafts, respec-
tively, P 0.05). It should also be noted that our second
graft group includes no patients with diabetes, a common
cause of death with functioning graft resulting from car-
diovascular diseases [25, 26].
Univariate and multivariate analyses showed that fac-
tors that might predict adverse outcome of second kidney
transplantation were HLA-DR matching and acute re-
jection episodes, while immunization level has no effect,
may be resulting from the matching policy. When the effect
of HLA MM on cadaver regraft survival was analyzed,
there was a clear advantage for recipients with fewer
HLA-DR, and to a lesser extent HLA-B, mismatched
allografts as previously reported for second transplants
[6, 22]. In addition, our data show that even one DR
MM significantly affected long-term graft survival. These
results suggest that allocation of kidney regrafts should
be based more on HLA-DR MM rather than HLA-A or
HLA-B.
Furthermore, our results confirmed that acute rejec-
tion occurrence is the posttransplant event that plays the
most significant role in second graft survival over the
time [27, 28]. The fact that the global rate of acute rejec-
tion was similar in both second and primary transplanta-
tion (29%) in our institution most likely contributed to
the similar overall survival data. The incidence of at least
one acute rejection episode strongly affects second graft
outcome and renal function, even with adequate HLA
matching. When our analysis was performed according
to time period, the year of transplantation appears as a
predominant parameter in the progressive reduction of
acute rejection. Thus, the incidence of acute rejection
decreased as graft survival improved. The deleterious
effect of acute rejection on graft survival still remained
significant beyond the first year of transplantation. The
impact of acute rejection most probably results from its
implication in chronic dysfunction of kidney allograft. The
most important predictor of chronic rejection is a previ-
ous episode of acute rejection [29]. Humar et al [30] showed
a low incidence of chronic rejection in recipients without
previous acute rejection, suggesting that immunologic
factors are the main determinants of long-term kidney
transplant outcome per se. It has also been recently
shown that the reduction of the rate of acute rejection
from 1988 to 1996 has resulted in lower rates of graft
failure due to chronic rejection [31].
Interestingly, we found that renal function at 12 months
strongly predicts the second transplant half-life, as pre-
viously demonstrated for primary grafts [16, 32]. More-
over, Hariharan et al [33] have demonstrated recently
that 1-year creatinine was an independent variable in-
fluencing long-term survival and recent improvements
in graft half-life could be explained by the preservation
of renal function within the first year posttransplantation.
Thus, creatinine at 12 months could be proposed as a
surrogate end point for clinical studies all the more be-
cause the acute rejection rate is decreasing.
It has been suggested that improvement in survival
rates for retransplant cadaveric transplantations reflects
mostly the impact of the efficacy of new immunosuppres-
sive drugs and better cross matching [6, 7, 14, 34]. How-
ever, time-dependent improvement of long-term trans-
plant survival could probably also result from multiple
other variables: better patient management, decreased
cold ischemia time, and immunization assessment. In our
cohort, all patients have been treated with the same
immunosuppressive regimen and only immunologic cri-
teria were applied for the selection of transplant alloca-
tion. HLA DR typing, anti-HLA class II antibody detec-
tion and B-cell cross match technique have been strongly
improved during the study period. Positive B-cell cross
match was allowed but no significant deleterious effect
was demonstrated in a recent study of our group that
included a majority of second grafts [15]. A low number
of patients received MMF or the microemulsion formula-
tion of CsA, which most likely does not contribute to
the overall data. In contrast, the method of CsA dosage
has also been improved.
CONCLUSION
Second graft long-term outcome, as well as primary,
shows an improved evolution according to the time pe-
riod resulting from a strong decrease in acute rejection
incidence. Our data suggest also that a strict class II
matching must be applied with optimal prevention of
acute rejection. In addition, the posttransplant function
at 1 year is predictive of long-term survival.
Reprint requests to Ste´phanie Coupel, M.D., ITERT—Institut de
Transplantation et de Recherche en Transplantation—and INSERM
U437, Immunointervention en Allo et Xe´notransplantations, 30, Bd Jean
Monnet, 44093 Nantes, cedex 01, France.
E-mail: stephanie.coupel@chu-nantes.fr
REFERENCES
1. Marcen R, Pascual J, Teruel JL, et al: Outcome of cadaveric
renal transplant patients treated for 10 years with cyclosporine.
Transplantation 72:57–62, 2001
2. Paul LC: Chronic renal transplant loss. Kidney Int 47:1491–1499,
1995
3. Womer KL, Vella JP, Sayegh MH: Chronic allograft dysfunction:
Mechanisms and new approaches to therapy. Semin Nephrol
20:126–147, 2000
4. Ojo AO, Wolfe RA, Agodoa LY, et al: Prognosis after primary
renal transplant failure and the beneficial effects of repeat trans-
plantation. Transplantation 66:1651–1659, 1998
5. Almond PS, Matas AJ, Gillingham K, et al: Risk factors for
Coupel et al: Long-term survival of second kidney transplants680
second renal allografts immunosuppressed with cyclosporine.
Transplantation 52:253–258, 1991
6. Gaston RS, Shroyer TW, Hudson SL, et al: Renal retransplanta-
tion: The role of race, quadruple immunosuppression, and the flow
cytometry cross-match. Transplantation 57:47–54, 1994
7. Mahoney RJ, Norman DJ, Colombe BW, et al: Identification of
high- and low-risk second kidney grafts. Transplantation 61:1349–
1355, 1996
8. Flechner SM, Lorber MI, Kerman RH, et al: Does cyclosporine
influence the results of cadaver retransplantation? Hum Immunol
14:305–313, 1985
9. Kerman RH, Kimball PM, Van Buren CT, et al: AHG and DTE/
AHG procedure identification of crossmatch-appropriate donor-
recipient pairings that result in improved graft survival. Trans-
plantation 51:316–320, 1991
10. Cho YW, Terasaki PI: Influence of rejection of the first transplant
on the outcome of subsequent transplants, in Retransplantation
(vol 29), edited by Touraine JL, Dordrecht, Kluwer Academic
Publishers, 1997, pp 65–78
11. Cho YW, Cecka JM: Cadaver-donor renal retransplants. Clin
Transpl 469–484, 1993
12. Delmonico FL, Tolkoff-Rubin N, Auchincloss H, Jr, et al: Sec-
ond renal transplantations. Ethical issues clarified by outcome;
outcome enhanced by a reliable crossmatch. Arch Surg 129:354–
360, 1994
13. Hirata M, Terasaki PI: Renal retransplantation. Clin Transpl
419–433, 1994
14. Bryan CF, Baier KA, Nelson PW, et al: Long-term graft survival
is improved in cadaveric renal retransplantation by flow cytometric
crossmatching. Transplantation 66:1827–1832, 1998
15. Le Bas-Bernardet S, Hourmant M, Valentin N, et al: Identifica-
tion of the antibodies involved in B cell crosmatch positivity in
renal transplantation. Transplantation 75:477–482, 2002
16. Giral-Classe M, Hourmant M, Cantarovich D, et al: Delayed
graft function of more than six days strongly decreases long-term
survival of transplanted kidneys. Kidney Int 54:972–978, 1998
17. Giral M, Pascuariello G, Karam G, et al: Acute graft pyelone-
phritis and long-term kidney allograft outcome. Kidney Int 61:
1880–1886, 2002
18. Naimark DM, Cole E: Determinants of long-term renal allograft
survival. Transplant Rev 8:93–113, 1994
19. Hiesse C, Neyrat N, Busson M: High rate of success in kidney
cadaveric retransplantation with optimal matching and potent im-
munosuppression. Transplant Proc 22:1909–1910, 1990
20. Sumrani NB, Miles AM, Daskalakis P, et al: Intermediate-term
outcome of renal retransplants in the cyclosporine era. ASAIO J
39:47–50, 1993
21. Karakayali H, Moray G, Demirag A: Long-term renal retrans-
plantation and graft survival rates at our center. Transplant Proc
30:762–763, 1998
22. Tejani A, Sullivan EK: Factors that impact on the outcome of
second renal transplants in children. Transplantation 62:606–611,
1996
23. Cecka JM: The UNOS Scientific Renal Transplant Registry. Clin
Transpl 1–16, 1998
24. Moss A, Najarian JS, Sutherland DE, et al: 5,000 kidney trans-
plants-a single-center experience. Clin Transpl 159–171, 2000
25. Matas AJ, Gillingham KJ, Sutherland DE: Half-life and risk
factors for kidney transplant outcome-importance of death with
function. Transplantation 55:757–761, 1993
26. Hirata M, Cho YW, Cecka JM, Terasaki PI: Patient death after
renal transplantation—An analysis of its role in graft outcome.
Transplantation 61:1479–1483, 1996
27. Pirsch JD, Ploeg RJ, Gange S, et al: Determinants of graft survival
after renal transplantation. Transplantation 61:1581–1586, 1996
28. Cosio FG, Pelletier RP, Falkenhain ME: Impact of acute rejec-
tion and early allograft function on renal allograft survival. Trans-
plantation 63:1611–1615, 1997
29. Almond PS, Matas A, Gilligham K, et al: Risk factors for chronic
rejection in renal allograft recipients. Transplantation 55:752–757,
1993
30. Humar A, Hassoun A, Kandaswamy R, et al: Immunologic fac-
tors: The major risk for decreased long-term renal allograft sur-
vival. Transplantation 68:1842–1846, 1999
31. Hariharan S, Johnson CP, Bresnahan BA, et al: Improved graft
survival after renal transplantation in the United States, 1988 to
1996. N Engl J Med 342:605–612, 2000
32. Opelz G: Effect of immunosuppressive therapy on graft half-life
projections. Transplant Proc 31:31S–33S, 1999
33. Hariharan S, McBride MA, Cherikh WS, et al: Post-transplant
renal function in the first year predicts long-term kidney transplant
survival. Kidney Int 62:311–318, 2002
34. Cecka JM, Terasaki PI: Repeating HLA antigen mismatches in
renal retransplants—A second class mistake? Transplantation 57:
515–519, 1994
